



Prostate Specific Antigen (PSA) Monoclonal Mouse Anti-PSA Clone 35H9

REF 014-1025

Ready-To-Use ■ 100 Tests/ 50 Tests

Concentrate ■ 1mL

INTENDED USE

IVD For in vitro diagnostic use.

Celerus monoclonal mouse anti-PSA, clone 35H9, is intended for laboratory use in identifying prostatic epithelial cells using light microscopy. It may be used with frozen tissue or with formalin-fixed paraffin-embedded tissue.

Positive results aid in the classification of normal and abnormal cells/ tissues and serve as an adjunct to conventional histopathology. The clinical interpretation of any positive staining or its absence should be complemented by morphological and histological studies with proper controls. Evaluations should be made by a qualified individual in conjunction with the patient's clinical history and other diagnostic test results.

Refer to the Wave Instrument Operator's Manual for additional information concerning Materials Required but Not Provided; Storage; Staining Procedure; Troubleshooting; Interpretation of Staining; and General Limitations.

SUMMARY AND EXPLANATION

PSA is present in the secretory and ductal epithelium of both normal and neoplastic prostatic tissue. The PSA antibody can be used to identify adenocarcinoma of the prostate in metastatic sites and to differentiate between prostate adenocarcinoma and urothelial carcinoma.

PRINCIPLE OF PROCEDURE

Immunohistochemistry is a multi-step process to identify specific cell markers within tissue biopsies or tumor specimens. The sequential steps include antigen retrieval (optional), antibody application, and antibody visualization followed by optional counterstaining. Specimens are then coverslipped and observed under light microscopy by trained personnel. Normally, multiple antibodies are tested to determine lineage and cell cycle markers. The Celerus Wave is an automated instrument that performs immunohistochemistry stains. For further information on the staining procedure, refer to the Celerus Wave Operator's Manual.

MATERIALS AND METHODS

Reagent Provided

Clone

35H9

Ig Class

IgG₁, kappa

Immunogen

PSA, isolated from human seminal fluid by affinity chromatography.

Ready-To-Use in Primary Antibody Cartridge

Celerus anti-PSA is provided with ProClin 300 as a preservative, in a Primary Antibody Cartridge (PAC), a self-contained dispenser of reagents. Each PAC contains sufficient reagent to complete 100 stained slides. PACs must remain upright to avoid spilling. PAC must be primed before first use. See Celerus Wave Operator's Manual for details.

Concentrated Antibody

Liquid

Liquid concentrated antibody is provided containing 15 mM sodium azide as a preservative and 1% bovine serum albumin as a carrier protein.

Lyophilized

Lyophilized antibody is provided containing 15mM sodium azide as a preservative. Reconstitute vial with 1.0 ml distilled water.

Dilution

The suggested dilution is 1:50- 1:100. This is a guide only and users should determine their own optimal working dilutions.

SPECIFICITY

Human prostate specific antigen.

MATERIALS REQUIRED BUT NOT PROVIDED

1. Wave instrument
2. Wave slide rack
3. Positively-charged microscope slides, appropriately labeled
4. Timer
5. Celerus Riptide for antigen retrieval (or equivalent)
6. Celerus Target Retrieval Solution (or equivalent)
7. Slide drying chamber
8. Xylene or xylene substitute
9. Reagent alcohol or ethyl alcohol
10. Distilled or deionized water
11. TBS wash buffer, pH 7.6
12. Positive and negative tissue controls
13. Celerus Negative Control Reagent (or equivalent)
14. Mounting Medium
15. Cover slips

STORAGE AND HANDLING

Ready-to-Use PAC, Liquid Concentrated and Lyophilized Antibody

Store reagent at 2-8 °C. Do not freeze. The reagent is stable until the expiration date on the container. Do not use reagent after the expiration date, as the activity cannot be ensured.

Reconstituted Antibody

For reconstituted antibody, the reagent is stable for at least two months when stored at 4 °C. For long-term storage it is recommended that aliquots of the antibody be stored at -20 °C. Repeated freezing and thawing of the antibody should be avoided.

There are no signs to indicate instability of this reagent. To ensure a valid staining assay, the use of positive and negative tissue controls is recommended. Contact your Celerus representative if there are stability concerns prior to the expiration date.

PRECAUTIONS

1. For professional users.
2. Minimize microbial contamination of reagents or an increase in nonspecific staining may occur.
3. As with any product derived from biological sources, proper handling procedures should be used.
4. A Material Safety Data Sheet is available for professional users on request.

5. ProClin 300 is classified per applicable European Community (EC) Directives as: Irritant (Xi). The following are the appropriate Risk (R) and Safety (S) phrases.



R36 Irritating to eyes

R43 May cause sensitization by skin contact

S24 Avoid contact with skin

S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice

S35 This material and its container must be disposed of in a safe way

S37/39 Wear suitable gloves and eye/face protection

S46 If swallowed, seek medical advice immediately and show this container or label.

WASTE DISPOSAL

Adhere to all local laws when disposing of the PAC.

PACKAGING DAMAGE

DO NOT USE a PAC if it is leaking, has leaked, has spilled, cannot be primed, or has visually apparent physical damage.

SPECIMEN COLLECTION AND HANDLING

Formalin-fixed paraffin embedded (FFPE) tissues, frozen tissues, or smears are suitable for use. Wave detection kits have been optimized for tissues fixed with 10% formalin. Ideally, each 4-6µ tissue section should be placed on charged slides on the lower 2/3 of the slide. Very large sections should be placed 1/4 inch below the lower end of the slide label.

Slides should be baked overnight at 37 °C, or at 60 °C for one hour.

Use standard histochemical techniques to deparaffinize processed slides. For uniformity of staining results, it is recommended that target retrieval be performed using the Celerus Riptide and Celerus Target Retrieval Solution (or equivalent) at 112 °C for 5 minutes. Avoid drying of the tissue specimen during this process. After all slides to be stained have been inserted and reagents mounted on the instrument, start the staining run.

When the slides have completed the staining run, remove them from the instrument, coverslip, and view under light microscopy.

PRODUCT-SPECIFIC LIMITATIONS

PSA antibody, when used on the Wave instrument, detects antigens that survive routine formalin fixation, tissue processing, and sectioning. Users who deviate from recommended test procedures are responsible for interpretation and validation of patient results.

RESULTS EXPECTED/

PERFORMANCE CHARACTERISTICS

Normal Tissues

PSA antibody stains prostate epithelial tissue. No specific staining pattern was seen in adrenal tissue, cerebellum and cerebrum, breast, heart, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, small intestine, spleen, stomach, testis, thyroid, tonsil, and uterus.

Abnormal Tissues

For neoplastic tissue, specific staining was seen in prostate carcinoma. No specific staining was seen in breast carcinoma, carcinoids, colon carcinoma, kidney carcinoma, leiomyoma, liver carcinoma, lung carcinoma, lymphoma, melanoma, ovarian cancer, pancreatic carcinoma, sarcoma, stomach carcinoma, teratoma, thyroid carcinoma, undifferentiated cancer, or vascular tumor.

REFERENCES

Gallee MPW, Visser-de Jong E, van der Korput JAGM, et al. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res 18: 181-187 (1990).

Harper CL, Lofts FJ, Otter M, Mansi JL. Prostate-specific antigen (PSA) immunohistochemistry in the presence of a normal serum PSA as an aid to diagnosis of adenocarcinoma of unknown primary site. Brit J Hosp Med. 55(6): 367-368 (1996).

Jurinic-Winkler C, Von der Kammer H, Horlbeck R, et al. Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen. Eur Urol. 24(4): 487-491 (1993).

Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 145: 907-923 (1991).

Nadji M, Tabei SZ, Castro A, et al. Prostatic-Specific Antigen: An immunohistologic marker for prostatic neoplasms. Cancer 48(5):1229-1232 (1981).



Vector Laboratories, Ltd.
3 Accent Park, Bakewell Road
Orton Southgate, Peterborough
PE2 6XS, England



Celerus Diagnostics
1005 Mark Avenue
Carpinteria, CA 93013 USA

TECHNICAL SUPPORT 888-444-3613
CUSTOMER SERVICE 888-444-8918

www.celerusdiagnostics.com